

Juliette Gair

NMC number: 05D0721E



Juliette originally studied for a BA(Hons) in Management Studies at the University of Leeds prior to moving to Cambridge and undertaking nurse training at Homerton College, School of Health Studies. She has been working at Addenbrooke's Hospital since 2005, originally working on the nurse rotation programme in gynaecology and ENT, before taking up a junior sister post in ENT and subsequently the skull base and NF2 nurse practitioner role in 2010. Juliette completed an MSc Advanced Practice in 2014 (Distinction, Anglia Ruskin University) with the major project looking at patient and clinician rated quality of life in vestibular schwannoma related to diagnostic factors and treatment outcomes.

The ENT background gives Juliette an in-depth knowledge of head and neck and otology issues and the combination of managerial and clinical training has acted as an ideal basis for the NF2 Eastern Region lead nurse post. Juliette works closely with the different clinicians in the Cambridge Skull Base Unit and she has a detailed knowledge of relevant conditions and symptom management. She can independently provide advice and support to patients diagnosed with NF2 and skull base conditions and reviews patients in outpatient clinics as well as providing assistance via telephone and email. Juliette is the lead for user/carer issues

and patient information for the skull base service and is actively involved in departmental audit, research, patient experience exercises and service reviews as well as being a member of the UK NF2 Research Group.

Publications

1. Ferner, R.E., Shaw, A., Evans, D.G., McAleer, D., Halliday, D., Parry, A., Raymond, F.L., Durie-Gair, J., Hanemann, C.O., Hornigold, R., Axon, P.R. and Golding, J.F., 2014. Longitudinal evaluation of quality of life in 288 patients with neurofibromatosis 2. *Journal of Neurology*, 261(5), 963-969.
2. Hexter, A., Jones, A., Joe, H., Heap, L., Smith, M.J., Wallace, A.J., Halliday, D., Parry, A., Taylor, A., Raymond, F.L., Shaw, A., Afridi, S., Obholzer, R., Axon, P.R., King, A.T., The English Specialist NF2 Research Group, Friedman, J.M. and Evans, D.G.R., 2015. Clinical and molecular predictors of mortality in neurofibromatosis 2: a UK national analysis of 1192 patients. *J Med Genet*, 52, 699-705.
3. Morris, K., Golding, J.F., Axon, P.R., Afridi, S., Blesing, C., Ferner, R.E., Halliday, D., Jena, R., Pretorius, P.M., the UK NF2 Research Group, Evans, D.G., McCabe, M.G. and Parry, A., 2016. Bevacizumab in Neurofibromatosis type 2 (NF2) related vestibular schwannomas: a nationally coordinated approach to delivery and prospective evaluation. *Neuro Oncol Practice*, first published online January 7, 2016
doi:10.1093/nop/npv065.
4. Tysome, J.R., Macfarlane, R., Durie-Gair, J., Donnelly, N.P., Mannion, R., Knight, R., Harris, F., Vanat, Z.H., Tam, Y.C., Burton, K., Hensiek, A., Raymond, F.L., Moffat, D.A. and Axon, P.R., 2012. Surgical Management of Vestibular Schwannomas and Hearing Rehabilitation in Neurofibromatosis Type 2. *Otology & Neurotology*, 33(3), 466-472.
5. Tysome, J.R., Axon, P.R., Donnelly, N.P., Durie-Gair, J., Evans, D.G., Ferner, R.E., Macfarlane, R., Mannion, R., Nduka, C., Morris, K., Pretorius, P.M., Rands, G., Rowe, J. and Taylor, A., 2014. Current concepts in management of Vestibular Schwannomas in Neurofibromatosis Type 2. *Current Otorhinolaryngology Reports*, 2(4), 248-255.
6. Walton, J., Donnelly N.P., Tam, Y.C., Joubert, I., Durie-Gair, J., Jackson, C., Mannion, R.A., Tysome, J.R., Axon, P.R. and Scoffings, D.J., 2014. MRI without magnet removal in Neurofibromatosis Type 2 patients with cochlear and auditory brainstem implants. *Otology & Neurotology*, 35(5), 821-825.